AbbVie Sees $3.35M in Unusual Options Activity as Calls Dominate Amid Stock Pullback

May 1, 2026

By TrendSpider Editor

AbbVie Sees $3.35M in Unusual Options Activity as Calls Dominate Amid Stock Pullback

AbbVie Inc. is drawing attention in the options market today, with a standout $2,820,000 call contract at the $210 strike driving the bulk of $3,354,869.90 in total unusual options premium on Friday, May 1, 2026. The stock is currently trading at $207.18, down 1.99% on the session, which places it in the lower half of its 52-week range of $176.57 to $244.81. Despite the intraday weakness, the options flow leans constructively, with two calls and one put surfacing across three unusual contracts.

Key Drivers of the ABBV Stock Move

Main Catalyst: Three unusual options contracts totaling $3,354,869.90 in premium were flagged today, headlined by a call at the $210 strike expiring December 18, 2026, with a size of 1,500 contracts and open interest utilization of 1,042%. That single contract accounted for $2,820,000 of the total premium, representing an outsized bet on ABBV moving above $210 within the next seven and a half months.
Bull Case: The dominant positioning is bullish. The December $210 call, with OI at 1,042% of prior open interest, signals a large new position being initiated rather than a roll or hedge. A second call at the $220 strike expiring June 18, 2026, added $238,580 in premium with a size of 604 contracts, reinforcing near-term upside conviction. Both calls are out of the money relative to the current $207.18 price, meaning traders are paying for directional exposure above current levels.
Bear Case: A put contract at the $180 strike expiring November 20, 2026, with 411 contracts and an OI utilization of 1,713%, introduces a notable hedge or downside bet. At $296,289.90 in premium, the $180 put sits well below the current price but reflects some market participant interest in protecting against a deeper decline toward the lower end of the 52-week range near $176.57.

The forward setup for ABBV is a tug of war between near-term selling pressure and longer-dated bullish positioning. The stock is down roughly 1.99% today and sits meaningfully below its 52-week high of $244.81, leaving significant ground to recover. The December call at $210 suggests at least one large player sees a catalyst or recovery window over the next several months. AbbVie's pipeline, including its immunology and oncology assets beyond the flagship Skyrizi and Rinvoq franchises, continues to be a focal point for institutional attention. Investors will be watching for any upcoming clinical readouts or business development moves that could serve as a re-rating event and justify the bullish options positioning seen today.

ABBV Unusual Options Activity

Contract 1: Call | Strike: $220 | Expiry: June 18, 2026 | Volume: 604 | Open Interest Utilization: 17% | Status: OTM | Premium: $238,580
Contract 2: Call | Strike: $210 | Expiry: December 18, 2026 | Volume: 1,500 | Open Interest Utilization: 1,042% | Status: OTM | Premium: $2,820,000
Contract 3: Put | Strike: $180 | Expiry: November 20, 2026 | Volume: 411 | Open Interest Utilization: 1,713% | Status: OTM | Premium: $296,289.90

ABBV Seasonality

May has historically been a mixed month for large-cap biopharma names, often influenced by conference season and mid-year pipeline updates. The placement of a June call expiring in just over six weeks suggests the buyer may be anticipating a near-term catalyst, potentially tied to upcoming medical conference presentations or quarterly earnings commentary.

ABBV Relative Performance

ABBV is currently trading at $207.18, representing a decline of 1.99% on the session. With a 52-week range spanning $176.57 to $244.81, the stock sits approximately 15.4% below its annual high, reflecting broader pharmaceutical sector pressure. The current price is roughly 17.3% above the 52-week low, suggesting the stock has recovered meaningfully from its trough but remains in a consolidation range well off peak levels.